Clinical Trial Update: A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study to identify the highest dose of Revumenib (SNDX-5613) after hematopoietic stem cell transplant in children with acute lymphoblastic leukemia, acut…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Mixed Phenotype Acute Leukemia

Drugs mentioned

• Revumenib (revumenib)

Snippet

Sponsor: Children's Oncology Group | Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Status: NOT_YET_RECRUITING